Allosteric Enhancers of A1 Adenosine Receptors: State of the Art and New Horizons for Drug Development
Abstract:Adenosine is an important autocoid, exerting its physiological effects on the human body by activation of four different G-protein- coupled-receptors (GPCRs) classified as A1, A2A, A2B, and A3. These receptors are coupled to secondary messenger systems including adenylate cyclase, inositol phosphate metabolism, and K+, KATP and Ca2+ channels. Pharmacological agents that increase the activation of A1 adenosine receptors in response to adenosine would be useful for treatment of cardiovascular, central nervous system, and inflammatory pathologies. Compounds that are able to enhance the activity of the A1-adenosine receptors by the endogenous ligand within specific tissues may have potential therapeutic advantages over non-endogenous agonists. Such an opportunity for intervention is provided by the concept of allosteric modulation of GPCRs. Therefore the use of allosteric enhancers to increase the responsiveness of the A1 receptors to endogenous adenosine at sites of its production is an appealing alternative to activation by exogenous agonists. This approach minimizes side effects because allosteric enhancers amplify the action of the agonist by stabilizing the agonist- A1-receptor&ndash G protein ternary complex. The allosteric enhancement of the GABAA receptor by benzodiazepines is the most famous and successful example of this strategy. The aim of this article is to give an overview of the results obtained in this field and discuss the opportunities and challenges that this class of ligands might offer for medicinal chemistry and pharmacology.
Keywords: 2-amino-3-benzoylthiophene; A1-adenosine receptor; ATCM (allosteric ternary complex model; Adenosine; Aminothiazole Derivatives; COPD; G protein ternary complex; G proteins; G-protein-coupled-receptors (GPCRs); Gi/Go family; K+, KATP; K-score; adenosine mediates bronchoconstriction; agonist-A1AR-G protein ternary complex; allosteric enhancer activity; allosteric ligand; allosteric modulators; antagonistic activities; antagonistic activity; antiarrythmic; anticonvulsant; autacoid adenosine; bitopic, ligands; butyric acid (GABA); cardiovascular tissues; central nervous system (CNS); chronic obstructive pulmonary disease (COPD); cyclase; enhancer; guanine nucleotides; increased endothelial cell permeability; indenothiazole; inflammation; inositol phosphate metabolism; ionotropic receptor; ischemic preconditioning (IPC); kinetic binding assay; lipophilic chlorine; lipophilic substituents; mucin production; multicenter, randomized; naphthoyl ring; neuropathic pain; neuropatic pain; neuroprotection; orthosteric antagonists; orthosteric radioligand; orthosteric site; placebo-controlled; protein kinase C; structure-activity analysis; therapeutic agent; α-subunit
Document Type: Research Article
Affiliations: Dipartimento di Scienze Farmaceutiche, Universita di Ferrara, Via Fossato di Mortara 17-19, 44100-Ferrara, Italy.
Publication date: 2010-10-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.